Ishii, Hiroki
Hashimoto, Tasuku
Sato, Aiko
Tanaka, Mami
Seki, Ryota
Ogawa, Michi
Kimura, Atsushi
Nakazato, Michiko
Iyo, Masaomi
Funding for this research was provided by:
The Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI Grants-in Aid for young scientists (20K16616)
Article History
Received: 7 December 2022
Accepted: 8 July 2024
First Online: 15 July 2024
Competing interests
: T.H. received research fundings from Japan Research Foundation for Clinical Pharmacology, Mitsubishi Foundation, and READYFOR Corporation. M.I. received consultant fees from Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., Abbott Japan Co., Ltd. and Janssen Pharmaceutical K.K., and reports honoraria from Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., MSD K.K., Eisai Co. Ltd., Daiichi-Sankyo Co. Ltd., Novartis Pharma K.K., Teijin Ltd., Shionogi & Co., Ltd., Hisamitsu Pharmaceutical Co., Inc. and Asahi Kasei Corporation. M.N. reports honoraria from Takeda Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Daiichi-Sankyo Co. Ltd., Novartis Pharma K.K., and Lundbeck Japan K.K. A.S. reports honoraria from Takeda Pharmaceutical Co., Ltd., and Lundbeck Japan K.K. A.K. reports honoraria from Takeda Pharmaceutical Co., Ltd. The other authors declare that they have no conflict of interest.